BillionToOne, Inc. (BLLN)
BillionToOne, Inc. is a precision diagnostics company focused on quantifying biology to create advanced molecular diagnostics. Their molecular counting platform enables the detection and measurement of DNA molecules at the single-count level, enhancing disease detection and personalized medicine.
Company Overview
BillionToOne is revolutionizing precision diagnostics with its molecular counting platform, enabling single-count DNA molecule detection for enhanced disease screening and personalized medicine, positioning it as a leader in the rapidly evolving molecular diagnostics market with a $3.78B market cap.
Investment Thesis
BillionToOne presents a compelling investment opportunity due to its innovative molecular counting platform and growing market presence in prenatal screening and oncology diagnostics. The company's UNITY Complete NIPS test addresses a significant market need for comprehensive and non-invasive prenatal risk assessment. The Northstar suite of liquid biopsy tests offers valuable tools for cancer diagnosis and monitoring, aligning with the increasing demand for personalized medicine. With a gross margin of 65.2%, BillionToOne demonstrates strong potential for profitability as it scales its operations. Key growth catalysts include expanding the clinical applications of its molecular counting platform and securing partnerships with healthcare providers and pharmaceutical companies. While the company currently operates at a loss with a profit margin of -5.6% and a P/E ratio of -260.34, strategic investments in R&D and market expansion are expected to drive revenue growth and improve profitability in the coming years.
Key Highlights
- Market Cap of $3.78B reflects investor confidence in BillionToOne's growth potential and innovative technology.
- Gross Margin of 65.2% indicates strong pricing power and efficient cost management in its diagnostic offerings.
- UNITY Complete, a non-invasive prenatal screen, addresses a significant market need for comprehensive fetal risk assessment.
- Northstar Select and Northstar Response provide valuable tools for cancer diagnosis and monitoring, aligning with the increasing demand for personalized medicine.
- Molecular counting platform enables the detection and measurement of DNA molecules at the single-count level, enhancing the sensitivity and accuracy of disease detection.
Competitors
Strengths
- Innovative molecular counting platform.
- Comprehensive non-invasive prenatal screening test (UNITY Complete).
- Liquid biopsy tests for cancer diagnosis and monitoring (Northstar).
- Strong intellectual property portfolio.
Weaknesses
- Currently operating at a loss with negative profit margin.
- Limited market presence compared to larger diagnostic companies.
- Reliance on a single technology platform.
- High R&D expenses.
Catalysts
- Ongoing: Expansion of UNITY Complete's market reach through strategic partnerships.
- Upcoming: Development and launch of new oncology diagnostic tests.
- Ongoing: Increasing adoption of liquid biopsy for cancer diagnosis and monitoring.
- Upcoming: Publication of clinical studies validating the performance of BillionToOne's diagnostic tests.
Risks
- Potential: Competition from established diagnostic companies with greater resources.
- Potential: Technological advancements by competitors rendering BillionToOne's technology obsolete.
- Ongoing: Regulatory changes affecting the approval and reimbursement of diagnostic tests.
- Potential: Economic downturn impacting healthcare spending and demand for diagnostic services.
- Ongoing: Reliance on a single technology platform exposes the company to potential disruptions.
Growth Opportunities
- Expansion of UNITY Complete's Market Reach: BillionToOne can expand the market reach of its UNITY Complete NIPS test by targeting new geographic regions and demographic segments. The global NIPS market is projected to reach $5.1 billion by 2027. By increasing awareness and adoption of UNITY Complete among healthcare providers and patients, BillionToOne can capture a larger share of this growing market. This includes strategic partnerships with OB/GYN practices and hospitals to integrate UNITY Complete into their standard prenatal care protocols.
- Development of New Oncology Diagnostic Tests: BillionToOne can leverage its molecular counting platform to develop new oncology diagnostic tests for early cancer detection, treatment monitoring, and personalized therapy selection. The liquid biopsy market is expected to reach $7.9 billion by 2025. By expanding its Northstar suite of liquid biopsy tests, BillionToOne can address the growing demand for non-invasive cancer diagnostics and personalized treatment strategies. This includes developing tests for a wider range of cancer types and biomarkers.
- Strategic Partnerships with Pharmaceutical Companies: BillionToOne can establish strategic partnerships with pharmaceutical companies to develop companion diagnostics for targeted therapies. Companion diagnostics are essential for identifying patients who are most likely to benefit from specific drugs. By collaborating with pharmaceutical companies, BillionToOne can accelerate the development and commercialization of its diagnostic tests and generate revenue through licensing agreements and royalties. This includes partnering with companies developing novel cancer therapies to develop companion diagnostics that can identify patients who are likely to respond to these treatments.
- Expansion into New Disease Areas: BillionToOne can expand its molecular counting platform into new disease areas beyond prenatal screening and oncology, such as infectious diseases and autoimmune disorders. The market for molecular diagnostics in infectious diseases is projected to reach $10.2 billion by 2027. By adapting its technology to detect and quantify biomarkers for these diseases, BillionToOne can diversify its product portfolio and address a broader range of clinical needs. This includes developing diagnostic tests for respiratory infections, sexually transmitted infections, and autoimmune disorders.
- Investment in Artificial Intelligence and Machine Learning: BillionToOne can invest in artificial intelligence (AI) and machine learning (ML) to enhance the accuracy and efficiency of its diagnostic tests. AI and ML can be used to analyze large datasets of genomic and clinical data to identify novel biomarkers and improve the performance of diagnostic algorithms. By integrating AI and ML into its platform, BillionToOne can further differentiate its products and maintain its competitive edge in the precision diagnostics market. This includes developing AI-powered tools for data analysis, interpretation, and reporting.
Opportunities
- Expansion into new disease areas beyond prenatal screening and oncology.
- Strategic partnerships with pharmaceutical companies.
- Increased adoption of liquid biopsy for cancer diagnosis and monitoring.
- Growing demand for personalized medicine and precision diagnostics.
Threats
- Competition from established diagnostic companies.
- Technological advancements by competitors.
- Regulatory changes affecting diagnostic testing.
- Economic downturn impacting healthcare spending.
Competitive Advantages
- Proprietary molecular counting platform provides a technological advantage.
- Strong intellectual property portfolio protects its diagnostic technologies.
- Established relationships with healthcare providers and hospitals.
- Reputation for accuracy and reliability in prenatal screening and cancer diagnostics.
About
BillionToOne, Inc., founded in 2016 and headquartered in Menlo Park, California, is a precision diagnostics company at the forefront of molecular diagnostics innovation. The company was established with the vision of quantifying biology to create more accurate and reliable diagnostic tools. Its core technology is a proprietary molecular counting platform, designed to detect and measure DNA molecules at the single-count level. This capability significantly enhances the sensitivity and accuracy of disease detection, enabling earlier and more precise diagnoses. BillionToOne's product portfolio includes UNITY Complete, a non-invasive prenatal screen (NIPS) that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw. This test offers comprehensive prenatal risk assessment, minimizing the need for invasive procedures. In oncology, BillionToOne offers Northstar Select, a liquid biopsy test that identifies mutations present in tumors, including deletions, insertions, and point mutations. Northstar Response provides longitudinal monitoring of cancer burden through methylation assessment, allowing clinicians to track treatment response and disease progression. BillionToOne's commitment to innovation and precision has established it as a key player in the diagnostics industry, driving advancements in prenatal screening and cancer management.
What They Do
- Develops a molecular counting platform for precise DNA molecule detection.
- Offers UNITY Complete, a non-invasive prenatal screen for fetal risk assessment.
- Provides Northstar Select, a liquid biopsy test for identifying tumor mutations.
- Offers Northstar Response, a test for longitudinal monitoring of cancer burden.
- Quantifies biology to create advanced molecular diagnostics.
- Enhances disease detection through single-count DNA molecule measurement.
Business Model
- Generates revenue through the sale of diagnostic tests, including UNITY Complete and Northstar.
- Partners with healthcare providers and hospitals to offer its diagnostic services.
- Focuses on developing and commercializing innovative diagnostic technologies.
- May generate revenue through licensing agreements and royalties from strategic partnerships.
Industry Context
The precision diagnostics industry is experiencing rapid growth, driven by advancements in genomics, proteomics, and molecular biology. The market is characterized by increasing demand for personalized medicine, early disease detection, and non-invasive diagnostic tools. BillionToOne is well-positioned within this landscape, leveraging its innovative molecular counting platform to address key market needs in prenatal screening and oncology. The company faces competition from established players in the diagnostics industry, as well as emerging companies developing novel diagnostic technologies. The global molecular diagnostics market is projected to reach $15.5 billion by 2027, growing at a CAGR of 9.2% from 2020 to 2027.
Key Customers
- Expectant parents seeking non-invasive prenatal screening.
- Oncologists and other healthcare professionals involved in cancer diagnosis and treatment.
- Hospitals and clinics offering prenatal and cancer diagnostic services.
- Pharmaceutical companies developing targeted therapies.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $84M | $2M | $0.03 |
| Q2 2025 | $67M | $-246,000 | $-0.01 |
| Q1 2025 | $59M | -$4M | $-0.09 |
| Q4 2024 | $45M | -$11M | $-0.26 |
Source: Company filings
Chart & Info
Price Chart
BillionToOne, Inc. (BLLN) stock price: $95.00 (+5.71, +6.39%)
Why Bull
- •BillionToOne seems to be generating buzz in the social trading community, suggesting growing awareness of their technology.
- •Recent insider activity hints at confidence in the company's future prospects.
- •The community's bullish views highlight the potential for BillionToOne to disrupt the prenatal testing market.
- •Market perception suggests investors see BillionToOne as an innovative player in genetic diagnostics.
Why Bear
- •The social trading community expresses concerns about the competitive landscape in genetic testing, which could impact BillionToOne's market share.
- •Bearish community views point to potential regulatory hurdles that BillionToOne might face.
- •Market perception indicates skepticism about the scalability of BillionToOne's technology.
- •Recent market developments suggest increased scrutiny of companies in the genetic testing space, potentially affecting BillionToOne's valuation.
Latest News
-
3 Growth Stocks Insiders Are Betting On
Simply Wall St. · Feb 16, 2026
-
Fund Slashes Chime Stake by Nearly $10 Million as Shares Sit 27% Below IPO Price
Motley Fool · Feb 14, 2026
-
BillionToOne Stock at $89: Why a New $19.1 Million Position Could Matter Now
Motley Fool · Feb 14, 2026
-
Navan Stock Plunges 60% From $25 IPO, but This $100 Million Stake Makes Up 20% of a Portfolio
Motley Fool · Feb 14, 2026
Technical Analysis
Rationale
AI-generated technical analysis for BLLN including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss BillionToOne, Inc. (BLLN) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for BLLN.
Make a Prediction
Set your price target for BillionToOne, Inc. (BLLN), choose a timeframe, and track your prediction accuracy.
Current price: $95.00
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BLLN.
Price Targets
Wall Street price target analysis for BLLN.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 10/100
Gross margin of 65.2% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates BLLN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
3 Growth Stocks Insiders Are Betting On
Fund Slashes Chime Stake by Nearly $10 Million as Shares Sit 27% Below IPO Price
BillionToOne Stock at $89: Why a New $19.1 Million Position Could Matter Now
Navan Stock Plunges 60% From $25 IPO, but This $100 Million Stake Makes Up 20% of a Portfolio
Frequently Asked Questions
What does BillionToOne, Inc. do?
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create advanced molecular diagnostics. The company's core technology is a molecular counting platform that detects and measures DNA molecules at the single-count level. This platform is used to develop and commercialize diagnostic tests for prenatal screening and cancer management. Its flagship product, UNITY Complete, is a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens. The company also offers Northstar Select and Northstar Response, liquid biopsy tests for cancer diagnosis and monitoring. BillionToOne aims to improve disease detection and personalized medicine through its innovative diagnostic solutions.
Is BLLN stock a good buy?
BLLN stock presents a mixed investment profile. The company's innovative molecular counting platform and strong gross margin of 65.2% suggest potential for future growth. The increasing demand for precision diagnostics and personalized medicine could drive revenue growth for BillionToOne's UNITY Complete and Northstar tests. However, the company's current negative profit margin of -5.6% and high P/E ratio of -260.34 indicate that it is not yet profitable. Investors should carefully consider the company's growth potential, competitive landscape, and financial performance before making an investment decision. Further, the $3.78B market cap needs to be considered in light of current financials.
What are the main risks for BLLN?
BillionToOne faces several risks, including competition from established diagnostic companies, technological advancements by competitors, and regulatory changes affecting diagnostic testing. The company's reliance on a single technology platform exposes it to potential disruptions if competitors develop superior technologies. Economic downturns could impact healthcare spending and demand for diagnostic services. Additionally, the company's current lack of profitability and high R&D expenses could strain its financial resources. Investors should be aware of these risks and carefully assess their potential impact on BillionToOne's future performance.
Is BLLN a good stock to buy?
Whether BLLN is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the BLLN MoonshotScore?
The MoonshotScore for BLLN is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is BLLN data updated?
BLLN stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to BLLN is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for BLLN?
Growth catalysts for BillionToOne, Inc. (BLLN) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes BillionToOne, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are BLLN's main competitors?
BillionToOne, Inc. (BLLN) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether BLLN has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about BLLN?
Wall Street analyst coverage for BLLN includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is BLLN's market cap?
Market capitalization (market cap) for BLLN is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows BLLN's current market cap alongside enterprise value and other valuation metrics.
How has BLLN stock performed recently?
BLLN's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing BLLN's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in BLLN?
Key risk categories for BLLN include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures BLLN's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling BLLN?
Insider trading activity for BLLN tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is BLLN a good stock for beginners?
BillionToOne, Inc. (BLLN) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is BLLN for first-time investors?
Every stock carries risk, including BillionToOne, Inc. (BLLN). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like BLLN.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Market projections are based on industry reports and analyst estimates.
- This analysis is for informational purposes only and should not be considered investment advice.